July 11, 2022
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

SymBio announces the publication of the results of its
Phase I/II clinical study of the rapid infusion (RI) administrationof TREAKISYM® liquid formulation
TOKYO, Japan, July 11, 2022 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “SymBio” or
the “Company”) today announced that the results of its Phase I/II clinical study in Japan toinvestigate the safety, tolerability, pharmacokinetics, and efficacy of the 10-minute administration ofTREAKISYM® ready-to-dilute (RTD) liquid formulation in combination with rituximab ("BR therapy")
in patients with previously untreated indolent B-cell non-Hodgkin lymphoma (iNHL) or mantle celllymphoma (MCL), and patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL),
were published in the Cancer Chemotherapy and Pharmacology (CCP) medical journal. Based on theresults of this clinical trial, TREAKISYM® RI administration was approved in February 2022.
For more information, the article can be viewed online at:https://link.springer.com/article/10.1007/s00280-022-04442-2
TREAKISYM® RI administration has a lower infusion volume (approximately 50 ml vs. 250 ml) and afaster infusion time (10 minutes vs. 60 minutes). In addition to the significant benefits to patients andhealthcare professionals resulting from TREAKISYM® RI administration’s reduced infusion time, thelower infusion volume means the infusion has lower salt content, which benefits patients with dietarysodium restrictions.
[Contact]
Investor Relations
Tel: +81 (0)3 5472 11251

About TREAKISYM®
TREAKISYM® (non-proprietary name: bendamustine hydrochloride), a cytocide anti-cancer drug firstused in Germany in the 1970s, is now widely used in more than 50 countries with indications for lowgrade non-Hodgkin’s lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia.
 TREAKISYM® Intravenous Infusion 100 mg was approved in October 2010 for manufacturing andmarketing for the indication of relapsed/refractory low-grade B-cell non-Hodgkin's lymphoma andmantle cell lymphoma in Japan.
 TREAKISYM® was approved for the additional indication of chronic lymphocytic leukemia in Japanin August 2016.
 TREAKISYM® was approved for the additional indications of first-line treatment of low-grade Bcell non-Hodgkin’s lymphoma and mantle cell lymphoma in Japan in December 2016.
 SymBio obtained approval for the marketing of TREAKISYM® Intravenous Drip Infusion
100mg/4mL (RTD, ready-to-dilute, liquid formulation) for all the above indications in September
2020.
 TREAKISYM® FD and RTD formulations were approved for the additional indication of relapsed orrefractory diffuse large B-cell lymphoma (r/r DLBCL) in March 2021 and April 2021, respectively.

About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who
previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen
Japan. In May 2016, the Company incorporated its wholly-owned subsidiary in the U.S., SymBio
Pharma USA, Inc. (Headquarters: Durham, North Carolina, President: Dr. Carolyn Yanavich).
The Company’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to bea leading global specialty biopharmaceutical company dedicated to addressing underserved medicalneeds.

2